8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Feb 12, 2026·SEC
Material company update
Dec 2, 2025·SEC
Benitec Biopharma Inc.(BNTC)Earnings, Financials & Key Ratios
BNTC•NASDAQ
Price updated Jun 19, 2026
AboutBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.Show more
- Revenue$0
- EBITDA-$41M-86.8%
- Net Income-$38M-74.3%
- EPS (Diluted)-1.05+60.8%
- ROE-52.46%+42.8%
BNTC Key Insights
Benitec Biopharma Inc. (BNTC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 35.6% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BNTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BNTC Price & Volume
Benitec Biopharma Inc. (BNTC) stock price & volume — 10-year historical chart
Loading chart...
BNTC Growth Metrics
Benitec Biopharma Inc. (BNTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-44.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.75%
Return on Capital
10 Years-165.05%
5 Years-272.92%
3 Years-374.51%
Last Year-57.58%
BNTC Recent Earnings
Benitec Biopharma Inc. (BNTC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.24+11.1%
$0.27
Rev
—
$5M
Q2 2026
May 13, 2026Metric
Actual
Est
EPS
$0.24+11.1%
$0.27
Rev
—
$5M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.26-13.0%
$0.23
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.22+37.1%
$0.35
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.24vs $0.27+11.1% | —vs $5M |
| Q2 2026 | May 13, 2026 | $0.24vs $0.27+11.1% | —vs $5M |
| Q1 2026 | Feb 12, 2026 | $0.26vs $0.23-13.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.22vs $0.35+37.1% | — |
Based on last 12 quarters of dataView full earnings history →
BNTC Peer Comparison
Benitec Biopharma Inc. (BNTC) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 QURE | 2.89B | 46.29 | -13.38 | -40.64% | -11.54% | -145.81% | 2.70 | |
 SLDB | 648.99M | 8.33 | -4.19 | -74.45% | 0.12 | |||
 DTIL | 87.36M | 6.81 | -1.88 | -50.12% | -98.7% | -81.24% | 0.31 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare BNTC vs Peers
Benitec Biopharma Inc. (BNTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BNTC Income Statement
Benitec Biopharma Inc. (BNTC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 195.88K | 204.39K | 8.07M | 97K | 59K | 73K | 75K | 0 | 0 | 0 |
Revenue Growth % | -24.23% | 4.34% | 3850.59% | -98.8% | -39.18% | 23.73% | 2.74% | -100% | - | - |
Cost of Goods Sold | 160K | 243.86K | 304.08K | -185K | 123K | 9K | 0 | 0 | 0 | 0 |
COGS % of Revenue | 81.68% | 119.31% | 3.77% | -190.72% | 208.47% | 12.33% | - | - | - | - |
Gross Profit | 35.88K▲ 0% | -39.47K▼ 210.0% | 7.77M▲ 19786.3% | 282K▼ 96.4% | -64K▼ 122.7% | 64K▲ 200.0% | 75K▲ 17.2% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | 18.32% | -19.31% | 96.23% | 290.72% | -108.47% | 87.67% | 100% | - | - | - |
Gross Profit Growth % | -80.18% | -210.01% | 19786.26% | -96.37% | -122.69% | 200% | 17.19% | -100% | - | - |
Operating Expenses | 12.23M | -39.47K | 7.77M | 8.56M | 13.53M | 17.92M | 19.16M | 22.49M | 41.77M | 53.94M |
OpEx % of Revenue | 6241.21% | -19.31% | 96.23% | 8827.84% | 22935.59% | 24545.21% | 25541.33% | - | - | - |
Selling, General & Admin | 5.35M | 4.72M | 3.23M | 5.57M | 6.51M | 6.65M | 6.38M | 6.99M | 23.43M | 34.74M |
SG&A % of Revenue | 2731.53% | 2308.48% | 39.94% | 5739.18% | 11037.29% | 9104.11% | 8509.33% | - | - | - |
Research & Development | 4.07M | 3.73M | 3.19M | 3M | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M | 19.2M |
R&D % of Revenue | 2079.58% | 1822.76% | 39.54% | 3093.81% | 11898.31% | 15441.1% | 17032% | - | - | - |
Other Operating Expenses | 2.8M | -8.48M | 1.35M | -5K | 0 | 0 | 0 | -108K | 0 | 0 |
Operating Income | -12.19M▲ 0% | -6.43M▲ 47.3% | 1.81M▲ 128.1% | -8.28M▼ 558.6% | -13.6M▼ 64.2% | -17.85M▼ 31.3% | -19.08M▼ 6.9% | -22.49M▼ 17.9% | -41.77M▼ 85.7% | -53.94M▲ 0% |
Operating Margin % | -6222.9% | -3143.94% | 22.36% | -8537.11% | -23044.07% | -24457.53% | -25441.33% | - | - | - |
Operating Income Growth % | 34.55% | 47.28% | 128.1% | -558.62% | -64.18% | -31.32% | -6.87% | -17.87% | -85.7% | - |
EBITDA | -12.06M | -6.32M | 1.92M | -7.91M | -13.17M | -17.46M | -18.7M | -22.15M | -41.37M | -53.46M |
EBITDA Margin % | -6157.73% | -3092.61% | 23.73% | -8151.55% | -22325.42% | -23920.55% | -24933.33% | - | - | - |
EBITDA Growth % | -2.68% | 47.6% | 130.31% | -512.67% | -66.59% | -32.57% | -7.09% | -18.43% | -86.79% | -44.07% |
D&A (Non-Cash Add-back) | 127.65K | 104.9K | 110.45K | 374K | 424K | 392K | 381K | 343K | 396K | 475K |
EBIT | -3.34M | -6.43M | 1.81M | -8.28M | -13.88M | -18.18M | -19.08M | -22.49M | -41.77M | -53.94M |
Net Interest Income | 0 | 0 | 85.28K | 62K | -6K | -32K | -33K | 0 | 0 | 1.59M |
Interest Income | 0 | 0 | 85.28K | 62K | 0 | 0 | 0 | 0 | 0 | 1.59M |
Interest Expense | 0 | 0 | 0 | 0 | 6K | 32K | 33K | 0 | 0 | 0 |
Other Income/Expense | 8.84M | 131.94K | 18.18K | 7K | -286K | -354K | -481K | 739K | 3.85M | 5.05M |
Pretax Income | -3.35M▲ 0% | -6.29M▼ 88.0% | 1.82M▲ 129.0% | -8.27M▼ 553.7% | -13.88M▼ 67.8% | -18.21M▼ 31.2% | -19.56M▼ 7.4% | -21.75M▼ 11.2% | -37.92M▼ 74.3% | -48.88M▲ 0% |
Pretax Margin % | -1708.71% | -3079.38% | 22.59% | -8529.9% | -23528.81% | -24942.47% | -26082.67% | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.35M▲ 0% | -6.29M▼ 88.0% | 1.82M▲ 129.0% | -8.27M▼ 553.7% | -13.88M▼ 67.8% | -18.21M▼ 31.2% | -19.56M▼ 7.4% | -21.75M▼ 11.2% | -37.92M▼ 74.3% | -48.88M▲ 0% |
Net Margin % | -1708.71% | -3079.38% | 22.59% | -8529.9% | -23528.81% | -24942.47% | -26082.67% | - | - | - |
Net Income Growth % | 75.76% | -88.05% | 128.98% | -553.67% | -67.78% | -31.16% | -7.44% | -11.19% | -74.32% | -44.49% |
Net Income (Continuing) | -3.35M | -6.29M | 1.82M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M | -48.88M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -63.56▲ 0% | -103.61▼ 63.0% | 28.45▲ 127.5% | -69.09▼ 342.9% | -27.27▲ 60.5% | -19.31▲ 29.2% | -14.12▲ 26.9% | -2.68▲ 81.0% | -1.05▲ 60.8% | -0.99▲ 0% |
EPS Growth % | 80.83% | -63.02% | 127.46% | -342.89% | 60.53% | 29.19% | 26.88% | 81.02% | 60.82% | 29.75% |
EPS (Basic) | -63.56 | -103.61 | 28.45 | -69.09 | -27.27 | -19.31 | -14.12 | -2.68 | -1.05 | - |
Diluted Shares Outstanding | 137.6K | 165.06K | 201.59K | 240.28K | 1.01M | 1.92M | 1.39M | 10.28M | 36.21M | 49.39M |
Basic Shares Outstanding | 137.59K | 165.06K | 201.59K | 240.28K | 1.01M | 1.92M | 1.39M | 10.26M | 36.21M | 49.39M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BNTC Balance Sheet
Benitec Biopharma Inc. (BNTC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 17.03M | 15.35M | 18.73M | 10.81M | 20.61M | 4.82M | 3.73M | 51.67M | 98.52M | 186.02M |
Cash & Short-Term Investments | 13.43M | 11.84M | 15.82M | 9.8M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M | 184.76M |
Cash Only | 13.35M | 11.82M | 15.7M | 9.8M | 19.77M | 4.06M | 2.48M | 50.87M | 97.74M | 184.76M |
Short-Term Investments | 76.84K | 22.04K | 126.76K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 3.39M | 3.03M | 2.54M | 59K | 25K | 3K | 55K | 229K | 33K | 3K |
Days Sales Outstanding | 6.31K | 5.41K | 114.64 | 222.01 | 154.66 | 15 | 267.67 | - | - | - |
Inventory | -65.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 281K | 385.66K | 1K | 87K | 15K | 14K | 13K | 579K | 741K | 1.25M |
Total Non-Current Assets | 387.3K | 326.16K | 478.33K | 935K | 771K | 1.15M | 735K | 536K | 1.07M | 983K |
Property, Plant & Equipment | 341.96K | 234.33K | 469.23K | 769K | 577K | 993K | 613K | 449K | 991K | 916K |
Fixed Asset Turnover | 0.57x | 0.87x | 17.21x | 0.13x | 0.10x | 0.07x | 0.12x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 45.34K | 91.82K | 9.1K | 9K | 194K | 160K | 122K | 87K | 83K | 67K |
Total Assets | 17.42M▲ 0% | 15.68M▼ 10.0% | 19.21M▲ 22.5% | 11.74M▼ 38.9% | 21.38M▲ 82.0% | 5.97M▼ 72.1% | 4.46M▼ 25.3% | 52.21M▲ 1069.6% | 99.59M▲ 90.8% | 187M▲ 0% |
Asset Turnover | 0.01x | 0.01x | 0.42x | 0.01x | 0.00x | 0.01x | 0.02x | - | - | 0.00x |
Asset Growth % | 17.26% | -10% | 22.53% | -38.86% | 82.04% | -72.06% | -25.26% | 1069.58% | 90.75% | 349.28% |
Total Current Liabilities | 864.51K | 1.87M | 2.64M | 1.14M | 1.37M | 2.53M | 3.98M | 4.92M | 1.8M | 3.27M |
Accounts Payable | 133.71K | 426.06K | 1.47M | 282K | 274K | 422K | 1.14M | 1.35M | 201K | 635K |
Days Payables Outstanding | 305.03 | 637.7 | 1.77K | -556.38 | 813.09 | 17.11K | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 192K | 0 | 0 | 0 | 0 | 0 | 482K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 158.3K | 1.82M | 1.09M | 459K | 276K | 400K | 1.82M | 475K | 1.25M | 2.16M |
Current Ratio | 19.70x | 8.20x | 7.10x | 9.51x | 15.05x | 1.90x | 0.94x | 10.49x | 54.67x | 56.82x |
Quick Ratio | 19.77x | 8.20x | 7.10x | 9.51x | 15.05x | 1.90x | 0.94x | 10.49x | 54.67x | 56.82x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 26.89K | 35.26K | 0 | 370K | 0 | 559K | 284K | 38K | 495K | 394K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 394K |
Capital Lease Obligations | 0 | 0 | 0 | 213K | 0 | 559K | 284K | 0 | 495K | 1.42M |
Deferred Tax Liabilities | 0 | 0 | 0 | 157K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 26.89K | 35.26K | 0 | 0 | 0 | 0 | 0 | 38K | 0 | 0 |
Total Liabilities | 891.4K | 1.91M | 2.64M | 1.51M | 1.37M | 3.09M | 4.26M | 4.96M | 2.3M | 3.67M |
Total Debt | 0 | 0 | 0 | 405K | 213K | 811K | 559K | 284K | 849K | 876K |
Net Debt | -13.35M | -11.82M | -15.7M | -9.4M | -19.56M | -3.25M | -1.92M | -50.58M | -96.89M | -183.88M |
Debt / Equity | - | - | - | 0.04x | 0.01x | 0.28x | 2.77x | 0.01x | 0.01x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | -8.19x | - | - | - | - | - | - | 3.44x |
Interest Coverage | - | - | - | - | -2312.67x | -568.00x | -578.21x | - | - | - |
Total Equity | 16.53M▲ 0% | 13.77M▼ 16.7% | 16.57M▲ 20.3% | 10.24M▼ 38.2% | 20.01M▲ 95.4% | 2.88M▼ 85.6% | 202K▼ 93.0% | 47.25M▲ 23290.1% | 97.3M▲ 105.9% | 183.33M▲ 0% |
Equity Growth % | 17.48% | -16.68% | 20.34% | -38.21% | 95.45% | -85.6% | -92.99% | 23290.1% | 105.92% | 386.38% |
Book Value per Share | 120.11 | 83.42 | 82.20 | 42.61 | 19.80 | 1.50 | 0.15 | 4.60 | 2.69 | 3.71 |
Total Shareholders' Equity | 16.53M | 13.77M | 16.57M | 10.24M | 20.01M | 2.88M | 202K | 47.25M | 97.3M | 183.33M |
Common Stock | 119.56M | 120.54M | 1K | 1K | 1K | 0 | 0 | 1K | 2K | 3K |
Retained Earnings | -104.32M | -107.86M | -108.87M | -116.64M | -130.12M | -148.33M | -167.89M | -190.26M | -228.18M | -260.91M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 1.29M | 1.1M | -1.86M | -1.95M | -1.46M | -1.25M | -830K | -892K | -839K | -952K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNTC Cash Flow Statement
Benitec Biopharma Inc. (BNTC) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.3M | -8.55M | 4.79M | -7.54M | -12.83M | -15.9M | -18.01M | -19.4M | -23.59M | -20.57M |
Operating CF Margin % | -4239.29% | -4183.48% | 59.32% | -7768.04% | -21749.15% | -21779.45% | -24016% | - | - | - |
Operating CF Growth % | 58.91% | -2.97% | 156.02% | -257.31% | -70.3% | -23.9% | -13.29% | -7.72% | -21.57% | -140.25% |
Net Income | -4.37M | -8.55M | 2.61M | -8.27M | -13.88M | -18.21M | -19.56M | -21.75M | -37.92M | -48.88M |
Depreciation & Amortization | 217K | 0 | 158K | 374K | 424K | 392K | 381K | 343K | 396K | 475K |
Stock-Based Compensation | 386K | 0 | 957.2K | 237K | 634K | 870K | 452K | 830K | 17.43M | 12.56M |
Deferred Taxes | -819.52K | 0 | -957.2K | 0 | 0 | 0 | -714K | 0 | 0 | 0 |
Other Non-Cash Items | -4.47M | 0 | 700K | 2K | -16K | 10K | 717K | 1K | -764K | 13.59M |
Working Capital Changes | 760K | 0 | 1.32M | 126K | 8K | 1.04M | 714K | 1.17M | -2.73M | -5.65M |
Change in Receivables | 0 | 0 | 607K | 2.4M | 28K | 1K | -50K | -176K | 197K | 8.07K |
Change in Inventory | 0 | 0 | 0 | -700K | -83K | -1.09M | -1.31M | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 740K | -1.7M | 55K | 1.09M | 1.36M | 0 | -2.38M | -4.66M |
Cash from Investing | -232.07K | -107.98K | -399.19K | -94K | -221K | -13K | -1K | -179K | -18K | -27.51K |
Capital Expenditures | -131.41K | -60.97K | -403.39K | -95K | -221K | -13K | -1K | -179K | -18K | -27.51K |
CapEx % of Revenue | 67.08% | 29.83% | 5% | 97.94% | 374.58% | 17.81% | 1.33% | - | - | - |
Acquisitions | 0 | 0 | 4K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 30.33K | -47.01K | 202 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 6.1M | 6.25M | -688.12K | 1.77M | 22.52M | 0 | 16.02M | 68.03M | 70.48M | 106.87M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 6.2M | 6.48M | 0 | 2.25M | 25.75M | 0 | 17.88M | 70.88M | 70.48M | 107.05M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.74M | -229.93K | -688.12K | -480K | -3.23M | 0 | -1.87M | -2.85M | 0 | -178.7K |
Net Change in Cash | -657.02K▲ 0% | -947.62K▼ 44.2% | 4.43M▲ 567.5% | -5.92M▼ 233.6% | 9.97M▲ 268.5% | -15.71M▼ 257.6% | -1.59M▲ 89.9% | 48.44M▲ 3154.2% | 46.93M▼ 3.1% | 81.23M▲ 0% |
Free Cash Flow | -8.44M▲ 0% | -8.61M▼ 2.1% | 4.39M▲ 150.9% | -7.63M▼ 273.9% | -13.05M▼ 71.1% | -15.91M▼ 21.9% | -18.01M▼ 13.2% | -19.58M▼ 8.7% | -23.61M▼ 20.5% | -20.59M▲ 0% |
FCF Margin % | -4306.37% | -4213.31% | 54.33% | -7865.98% | -22123.73% | -21797.26% | -24017.33% | - | - | - |
FCF Growth % | 58.78% | -2.09% | 150.94% | -273.94% | -71.07% | -21.9% | -13.2% | -8.71% | -20.55% | -10.22% |
FCF per Share | -61.31 | -52.17 | 21.76 | -31.75 | -12.92 | -8.28 | -13.00 | -1.91 | -0.65 | -0.42 |
FCF Conversion (FCF/Net Income) | 2.48x | 1.36x | 2.63x | 0.91x | 0.92x | 0.87x | 0.92x | 0.89x | 0.62x | 0.42x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNTC Key Ratios
Benitec Biopharma Inc. (BNTC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -21.88% | -41.55% | 12.02% | -61.73% | -91.79% | -159.08% | -1268.61% | -91.68% | -52.46% | -34.82% |
Return on Invested Capital (ROIC) | -504.01% | -187.97% | 95.77% | -723.56% | -1573.61% | -31507.06% | - | - | - | 24591.79% |
Gross Margin | 18.32% | -19.31% | 96.23% | 290.72% | -108.47% | 87.67% | 100% | - | - | - |
Net Margin | -1708.71% | -3079.38% | 22.59% | -8529.9% | -23528.81% | -24942.47% | -26082.67% | - | - | - |
Debt / Equity | - | - | - | 0.04x | 0.01x | 0.28x | 2.77x | 0.01x | 0.01x | 0.00x |
Interest Coverage | - | - | - | - | -2312.67x | -568.00x | -578.21x | - | - | - |
FCF Conversion | 2.48x | 1.36x | 2.63x | 0.91x | 0.92x | 0.87x | 0.92x | 0.89x | 0.62x | 0.42x |
Revenue Growth | -24.23% | 4.34% | 3850.59% | -98.8% | -39.18% | 23.73% | 2.74% | -100% | - | - |
Related:BNTC Dividend History·BNTC Revenue History·BNTC Price History·BNTC P/E History·BNTC Financial Ratios·BNTC Institutional Holders
BNTC SEC Filings & Documents
Benitec Biopharma Inc. (BNTC) SEC filings — annual & quarterly reports (10-K, 10-Q)
BNTC Frequently Asked Questions
Benitec Biopharma Inc. (BNTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Benitec Biopharma Inc. (BNTC) grew revenue by 0.0% over the past year. Growth has been modest.
Benitec Biopharma Inc. (BNTC) reported a net loss of $48.9M for fiscal year 2025.
Dividend & Returns
Benitec Biopharma Inc. (BNTC) has a return on equity (ROE) of -52.5%. Negative ROE indicates the company is unprofitable.
Benitec Biopharma Inc. (BNTC) had negative free cash flow of $20.6M in fiscal year 2025, likely due to heavy capital investments.